Can engineered immune cells target a common ovarian cancer protein?
NCT ID NCT02498912
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This early-phase trial tests a new type of cell therapy for people with recurrent solid tumors, especially ovarian cancer, that have a specific protein called MUC16 on their surface. The treatment involves collecting a patient's own immune cells, genetically modifying them to recognize and attack MUC16 and to produce a substance that boosts their activity, and then infusing them back into the patient. The main goal is to find a safe dose of these modified cells and to see what effects they have on the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Genetically modified T cells (4H11-28z/fIL-12/EGFRt+) plus cyclophosphamide and fludarabine
- What this could lead to
- If successful, this could lead to a new treatment option for recurrent ovarian and other solid tumors that have not responded to standard chemotherapy.
- What could go wrong
- This is an early-phase trial with a small number of participants, so safety and effectiveness are not yet established. The modified T cells may cause severe side effects or may not shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can heated chemotherapy improve ovarian cancer outcomes?
- Can a new imaging tracer outperform standard scans in finding hidden tumors?
- Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
- Experimental pill takes on Hard-to-Treat ovarian cancer